Breaking Finance News

Obalon Therapeutics (NASDAQ:OBLN) target price raised to $6.00, issued a report today by Northland Capital

Obalon Therapeutics (NASDAQ:OBLN) had its target price raised to $6.00 by Northland Capital in a report released 6/21/2017. The new target price indicates a possible downside of -0.45% based on the company's last stock close price.

Yesterday Obalon Therapeutics (NASDAQ:OBLN) traded 2.67% higher at $10.96. The company’s 50-day moving average is $9.71 and its 200-day moving average is $9.50. The last stock close price is up 5.23% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 128,606 shares of the stock were exchanged, up from an average trading volume of 53,480

See Chart Below

Obalon Therapeutics (NASDAQ:OBLN)

Obalon Therapeutics has a 52 week low of $8.27 and a 52 week high of $15.88 The company’s market cap is currently $0.

General Information About Obalon Therapeutics (NASDAQ:OBLN)

Obalon Therapeutics, Inc. is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.